Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055029 · ClinicalTrials.gov registry record
Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis
A clinical trial of Retinoschisis, sponsored by National Eye Institute (NEI).
- Active
- Registry status
- 351
- Enrollment target
- 2
- Study locations
NCT00055029: Active study of Retinoschisis, sponsored by National Eye Institute (NEI).
NCT00055029 is a study of Retinoschisis that is active but no longer recruiting, run by National Eye Institute (NEI). The registered enrollment target is 351 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055029, a study of Retinoschisis, is active but no longer recruiting, sponsored by National Eye Institute (NEI).
- ACTIVE NOT RECRUITING
- Registry status
- 351 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will explore the causes and eye problems of X-linked juvenile retinoschisis (XLRS), an inherited disease that causes vision loss primarily in young males. The vision loss, which worsens over time, is a result of schisis, or splitting, of the layers of the retina (tissue that lines the back of the eye). A better understanding of why and how XLRS develops might lead to improved treatments. Patients 9 months of age and older with XLRS and females who are suspected carriers of the gene responsible for the disease (such as the mother of the patient) may be eligible for this study. Other family members of patients also may be enrolled. Patients will undergo the following tests and procedures: * Personal and family medical history to review past and current medical conditions and treatments, particularly regarding eye disease, and to construct a family tree. * Eye examination to assess visual acuity (eye chart test) and examine pupils, lens, retina, and eye movements. The pupils will be dilated with drops for this examination. * Photography of the retina to help evaluate the status of the retina. * Specialized eye tests to evaluate color vision, field of vision, and ability to see in the dark. * Electroretinogram (ERG) to examine what happens to the eyes after a flash of bright light. For this test, the patient sits in a dark room for 30 minutes with his or her eyes patched. Then, a small silver disk electrode is taped to the forehead, the eye patches are removed, the surface of the eye is numbed with eye drops and contact lenses are placed on the eyes. The patient looks inside a large empty bowl and then a light flashes, first in the dark and then with a light turned on inside the bowl. The contact lenses sense small electrical signals generated by the retina when the light flashes. * Blood test to examine DNA for genetic study of XLRS. Family members will provide a blood sample for genetic study.
Primary Outcome
The overall goal of this protocol is to better understand the etiology of XLRS disease to facilitate further research to identify a potential treatment for the disease.
Conditions Studied
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Michigan
- William Beaumont Hospital - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2003-05-19 |
What the registry record for NCT00055029 still lists
NCT00055029 is an observational study that tracks outcomes without assigning an intervention. The registered 351 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Retinoschisis appearing as the primary indexed condition, and to 0 interventions.
NCT00055029 reports a single indexed study location in Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT00055029 about?
NCT00055029 is a clinical study titled "Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis". This study will explore the causes and eye problems of X-linked juvenile retinoschisis (XLRS), an inherited disease that causes vision loss primarily in young males. The vision loss, which worsens over time, is a result of schisis, or splitting, of the layers of the retina (tissue that lines the bac...
What is the current status of trial NCT00055029?
This trial is currently active not recruiting. The enrollment target is 351 participants. The study started on 2003-05-19.
What conditions does trial NCT00055029 study?
This clinical trial studies the following conditions: Retinoschisis.
Who is sponsoring clinical trial NCT00055029?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055029 being conducted?
This trial has 2 study locations across Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinoschisis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06241456 · 351 participants · Phase 1
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- NCT06576726 · 351 participants
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
- NCT07043400 · 351 participants · Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT07261423 · 351 participants · NA
Pollution Intervention to Impact Kids Asthma Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI